Introducing New Vaccines in Developing Countries

Sonali Kochhar; Barbara Rath; Lea D Seeber; Gabriella Rundblad; Ali Khamesipour; Mohammad Ali


Expert Rev Vaccines. 2013;12(12):1465-1478. 

In This Article

Five-year View

Country and regional stakeholders should collaborate closely in determining the most suitable and appropriate vaccines to be selected for introduction to maximize the effect of the immunization program. Priority lists should be updated continuously based on consensus processes. This might help to limit the cost of vaccines. Vaccines high on the list for the introduction to developing countries should include human papilloma virus vaccines, rotavirus vaccines, as well as pneumococcal and cholera vaccines in endemic areas. Additional research is warranted on the impact of influenza in developing countries. A universal flu vaccine is urgently needed to allow effective disease prevention in low-resource settings.

New business models and market incentives should be developed for the introduction of more licensed vaccines in low-resource settings. Innovative ways of financing will be sought, including the mobilization of public–private initiatives, crowd financing, on-demand financing and innovative fundraising models from different areas.

Innovative IT tools need to be implemented. The comprehensive analysis of large databases will enable enhanced safety and efficaciousness analyses as well as real-time monitoring of disease and vaccine safety signals. Real-time monitoring of vaccine rumors via social media networks is useful. Issues that need to be resolved include ownership of individual-level patient data, ethics and liability, data protection and stewardship.

The dissemination of vaccine know-how should be enhanced. Lessons learned, guidelines for implementation and relevant data from successful previous vaccine introduction campaigns should be compiled and shared in a national, regional and global context.